UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours

Acta neuropathologica, 2014-02, Vol.127 (2), p.307-309

2014

Volltextzugriff (PDF)

Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome

Neuro-oncology (Charlottesville, Va.), 2023-12, Vol.25 (12), p.2273-2286

2023

Volltextzugriff (PDF)

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

Acta neuropathologica, 2012-04, Vol.123 (4), p.501-513

2012

Volltextzugriff (PDF)

Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types

Acta neuropathologica, 2013-12, Vol.126 (6), p.943-946

2013

Volltextzugriff (PDF)

Rapid Diagnosis of Medulloblastoma Molecular Subgroups

Clinical cancer research, 2011-04, Vol.17 (7), p.1883-1894

2011

Volltextzugriff (PDF)

Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma

Journal of clinical oncology, 2013-08, Vol.31 (23), p.2927-2935

2013

Volltextzugriff (PDF)

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

Oncotarget, 2015-11, Vol.6 (36), p.38827-38839

2015

Volltextzugriff (PDF)

Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death

Acta neuropathologica, 2012-05, Vol.123 (5), p.711-725

2012

Volltextzugriff (PDF)

TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas

Journal of clinical oncology, 2011-04, Vol.29 (12), p.e344-e346

2011

Volltextzugriff (PDF)

Genome-Wide Analysis of Alternative Splicing in Medulloblastoma Identifies Splicing Patterns Characteristic of Normal Cerebellar Development

Cancer research (Chicago, Ill.), 2011-03, Vol.71 (6), p.2045-2055

2011

Volltextzugriff (PDF)

Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs

Molecular therapy. Nucleic acids, 2017-12, Vol.9 (C), p.22-33

2017

Volltextzugriff (PDF)

Treating childhood acute lymphoblastic leukemia in Malawi

Haematologica (Roma), 2013-01, Vol.98 (1), p.e1-e3

2013

Volltextzugriff (PDF)

PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i159-i159

2022

Volltextzugriff (PDF)

OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING

Neuro-oncology (Charlottesville, Va.), 2021-06, Vol.23 (Supplement_1), p.i38-i38

2021

Volltextzugriff (PDF)

Abstract 1275: Identification of cancer-specific synthetic lethal genes as novel therapeutic targets

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1275-1275

2020

Volltextzugriff (PDF)

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION

Neuro-oncology (Charlottesville, Va.), 2021-06, Vol.23 (Supplement_1), p.i11-i11

2021

Volltextzugriff (PDF)

The use of anthracyclines in the treatment of endemic Burkitt lymphoma

British journal of haematology, 2017-06, Vol.177 (6), p.984-990

2017

Volltextzugriff (PDF)

Abstract LB-324: A whole chromosome aberration phenotype in non-WNT/non-SHH tumors predicts outcome within standard-risk medulloblastomas from the HIT-SIOP-PNET4 clinical trial

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.LB-324-LB-324

2018

Volltextzugriff (PDF)

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance

Oncogene, 2015-09, Vol.34 (36), p.4746-4757

2015

Volltextzugriff (PDF)

MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (Supplement_3), p.iii410-iii410

2020

Volltextzugriff (PDF)

MBRS-32. METHYLATION PROFILE IN A RETROSPECTIVE SERIES OF SPANISH PEDIATRIC MEDULLOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2018-06, Vol.20 (suppl_2), p.i135-i135

2018

Volltextzugriff (PDF)

MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-06, Vol.25 (Supplement_1), p.i64-i65

2023

Volltextzugriff (PDF)

MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

Neuro-oncology (Charlottesville, Va.), 2022-06, Vol.24 (Supplement_1), p.i107-i107

2022

Volltextzugriff (PDF)

QOS-26HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN HIT-SIOP-PNET4 TRIAL SURVIVORS: DIFFERENCES BETWEEN MEDULLOBLASTOMA MOLECULAR SUBGROUPS

Neuro-oncology (Charlottesville, Va.), 2016-06, Vol.18 (suppl 3), p.iii150.5-iii151

2016

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

TERT promoter mutation and aberrant hypermethylation are associated with elevated expression in medulloblastoma and characterise the majority of non-infant SHH subgroup tumours

Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease

Clinical outcome of pediatric medulloblastoma patients with Li–Fraumeni syndrome

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

Histologically defined central nervous system primitive neuro-ectodermal tumours (CNS-PNETs) display heterogeneous DNA methylation profiles and show relationships to other paediatric brain tumour types

Rapid Diagnosis of Medulloblastoma Molecular Subgroups

Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial

Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death

TP53 mutations in favorable-risk Wnt/Wingless-subtype medulloblastomas

Genome-Wide Analysis of Alternative Splicing in Medulloblastoma Identifies Splicing Patterns Characteristic of Normal Cerebellar Development

Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs

Treating childhood acute lymphoblastic leukemia in Malawi

PATH-06. Molecular subgrouping of medulloblastoma via low-depth whole genome bisulfite sequencing

OMIC-06. MOLECULAR SUBGROUPING OF MEDULLOBLASTOMA VIA LOW-DEPTH WHOLE GENOME BISULFITE SEQUENCING

Abstract 1275: Identification of cancer-specific synthetic lethal genes as novel therapeutic targets

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION

The use of anthracyclines in the treatment of endemic Burkitt lymphoma

Abstract LB-324: A whole chromosome aberration phenotype in non-WNT/non-SHH tumors predicts outcome within standard-risk medulloblastomas from the HIT-SIOP-PNET4 clinical trial

Cross-species epigenetics identifies a critical role for VAV1 in SHH subgroup medulloblastoma maintenance

MBRS-69. METABOLITE PROFILING OF SHH MEDULLOBLASTOMA IDENTIFIES A SUBSET OF CHILDHOOD TUMOURS ENRICHED FOR HIGH-RISK MOLECULAR BIOMARKERS AND CLINICAL FEATURES

MBRS-32. METHYLATION PROFILE IN A RETROSPECTIVE SERIES OF SPANISH PEDIATRIC MEDULLOBLASTOMA

MDB-15. CLINICAL CHARACTERISTICS AND OUTCOME OF CHILDHOOD LI-FRAUMENI SYNDROME MEDULLOBLASTOMA PATIENTS

MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome

QOS-26HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN HIT-SIOP-PNET4 TRIAL SURVIVORS: DIFFERENCES BETWEEN MEDULLOBLASTOMA MOLECULAR SUBGROUPS

Suchergebnisse filtern